Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.

Abstract

Targeted gene therapy is a promising approach for treating prostate cancer after the discovery of prostate cancer-specific promoters such as prostate-specific antigen, rat probasin, and human glandular kallikrein. However, these promoters are androgen dependent, and after castration or androgen ablation therapy, they become much less active or sometimes inactive. Importantly, the disease will inevitably progress from androgen-dependent (ADPC) to castration-resistant prostate cancer (CRPC), at which treatments fail and high mortality ensues. Therefore, it is critical to develop a targeted gene therapy strategy that is effective in both ADPC and CRPC to eradicate recurrent prostate tumors. The human telomerase reverse transcriptase-VP16-Gal4-WPRE integrated systemic amplifier composite (T-VISA) vector we previously developed, which targets transgene expression in ovarian and breast cancer, is also active in prostate cancer. To further improve its effectiveness based on androgen response in ADPC progression, the ARR2 element (two copies of androgen response region from rat probasin promoter) was incorporated into T-VISA to produce AT-VISA. Under androgen analog (R1881) stimulation, the activity of AT-VISA was increased to a level greater than or comparable to the cytomegalovirus promoter in ADPC and CRPC cells, respectively. Importantly, AT-VISA demonstrated little or no expression in normal cells. Systemic administration of AT-VISA-BikDD encapsulated in liposomes repressed prostate tumor growth and prolonged mouse survival in orthotopic animal models as well as in the transgenic adenocarcinoma mouse prostate model, indicating that AT-VISA-BikDD has therapeutic potential to treat ADPC and CRPC safely and effectively in preclinical setting.

• Authors: Xiaoming Xie, Yanan Kong, Hailin Tang, Lu Yang, Jennifer L Hsu, Mien-Chie Hung
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 13 Issue 7 Pg. 1813-25 (Jul 2014) ISSN: 1538-8514 [Electronic] United States
• PMID: 24785255 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: ©2014 American Association for Cancer Research.

Chemical References

• Adaptor Proteins, Signal Transducing
• Apoptosis Regulatory Proteins
• BIK protein, human
• Bik protein, mouse
• Membrane Proteins
• Mitochondrial Proteins

Topics

• Adaptor Proteins, Signal Transducing (biosynthesis, genetics)
• Animals
• Apoptosis (genetics)
• Apoptosis Regulatory Proteins (biosynthesis, genetics)
• Genetic Therapy (methods)
• Humans
• Male
• Membrane Proteins (biosynthesis, genetics)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred C57BL
• Mice, Nude
• Mitochondrial Proteins (biosynthesis, genetics)
• Molecular Targeted Therapy
• Neoplasms, Hormone-Dependent (genetics, therapy)
• Prostatic Neoplasms (genetics, therapy)
• Prostatic Neoplasms, Castration-Resistant (genetics, therapy)
• Random Allocation
• Transfection
• Transgenes
• Xenograft Model Antitumor Assays